Navigation Links
BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2013 Financial Results on Friday, May 10, 2013
Date:5/3/2013

LYNBROOK, N.Y., May 3, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S., announced today that it will host a conference call and live audio webcast at 8:30 a.m. EDT on Friday, May 10, 2013 to report its first quarter 2013 financial results and provide a corporate update.

In order to participate in the conference call, please dial 1-800-860-2442 (domestic) or 1-412-858-4600 (international). The live webcast can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com or you may use the link: http://www.videonewswire.com/event.asp?id=93618.

A replay of the call will be available one hour after the end of the conference on May 10, 2013 until 9:00 a.m. EDT on May 27, 2013. To access the replay, please dial 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and reference the access code 10028021. The archived webcast will be available for 90 days in the Investor Relations section of BioSpecifics' website at www.biospecifics.com.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is marketed as XIAFLEX® in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord in the palm by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc., and is approved for Dupuytren's contracture in the EU and Canada. XIAFLEX is also in clinical development for the treatment of several additional promising indications. The U.S. Food & Drug Administration (FDA) has accepted Auxilium's supplemental Biologics License Application (sBLA) for filing for XIAFLEX for the potential treatment of Peyronie's disease.  The FDA is expected to take action on the application by September 6, 2013, and, if approved, XIAFLEX will be the first and only biologic treatment indicated for Peyronie's disease. Auxilium is also testing XIAFLEX for frozen shoulder syndrome (adhesive capsulitis) and cellulite. Auxilium has reported positive top-line data from a Phase IIa frozen shoulder study and expects to initiate the next phase trial in the second half of 2013. BioSpecifics is currently managing the clinical development of XIAFLEX for the treatment of human and canine lipomas, which are both in Phase II clinical trials, with top-line data from both trials expected in the second half of 2013. Auxilium is currently partnered with Asahi Kasei Pharma Corporation for the development and commercialization of XIAFLEX for Dupuytren's contracture and Peyronie's disease in Japan and with Actelion Pharmaceuticals Ltd. for these same indications in Canada, Australia, Brazil and Mexico.  For more information, please visit www.biospecifics.com.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
2. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2012 Financial Results on August 9, 2012
3. BioSpecifics Technologies Corp. To Present at Stifel Nicolaus Weisel Healthcare Conference 2012
4. BioSpecifics Technologies Corp. to Present at Two Upcoming Investor Conferences in September
5. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2012 Financial Results on November 8, 2012
6. BioSpecifics Technologies Corp. to Webcast, Live, at RetailInvestorConferences.com on December 6th
7. BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences
8. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2012 Financial Results on Tuesday, March 12, 2013
9. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2012 Financial Results
10. West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services
11. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... -- As the latest Obamacare repeal effort moves is debated, ... and Lindsey Graham (R-SC) medical device market ... is in an odd place.  The industry wants repeal ... on medical device sales passed along with the Affordable ... visits and hospital customers with the funding to invest ...
(Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
(Date:9/9/2017)... Sept. 8, 2017 ... MRI Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, September 18 th ... offering free MRI brain scans to the public.Where:  ... parked at 501 K Street NW, Washington, D.C.What:BTF brings its nationwide initiative, ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... 2017 , ... On Sunday, September 24, hundreds will gather at Flo Jo ... considered the fastest woman of all time. Flo Jo passed away from complications ... the National Anthem. Mary was a contestant on the 2012 season of America’s ...
(Date:9/22/2017)... (PRWEB) , ... September 22, 2017 , ... ... assembles Passive House buildings, and Richard Pedranti Architect (RPA), a full-service ... from the strategic partner’s Solsken Line of Model Homes . Independently, Ecocor ...
(Date:9/22/2017)... ... September 22, 2017 , ... SABRE is ... Sweepstakes.,  , Molli C., a graduate student from Sonora, California, who will begin ... at St. Thomas University in Miami, Florida, was selected from a pool of ...
(Date:9/22/2017)... ... ... “Cursed with a Curse: The Truth about Tithing”: a ... when breaking free from this misconception. “Cursed with a Curse: The Truth about ... Christian Faith Publishing, Lysa M. Harrison’s new book is a powerful and thought-provoking ...
(Date:9/22/2017)... ... 2017 , ... "Success Files," a short- and long-form documentary ... a disease estimated to affect the lives of more than 5 million Americans ... a leading voice in the fight for cure and research into the disease, ...
Breaking Medicine News(10 mins):